Bio-Path Q2 net loss $4.2M ($0.53/sh); positive AML Phase 2 data for prexigebersen

BIO-PATH HOLDINGS, INC.

2023-Q2 EPS reported -$1.19

Net loss $4.2M ($0.53/sh) vs $3.0M ($0.42/sh) a year ago; R&D spend up to $3.1M from $1.9M.
Cash $3.4M at June 30, down from $10.4M at Dec 31, 2022; operating cash burn $6.9M for H1 2023.
Positive interim Phase 2 data for prexigebersen in AML: well-tolerated, compelling efficacy in newly diagnosed and relapsed/refractory patients.
Company plans to file for regulatory designations to accelerate pathway for prexigebersen in AML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIO-PATH HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: net income $4.2 million, or $0.53 per share.

Period: the second quarter ended June 30, 2023
Net income: $4.2 million, or $0.53 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.2 million, or $0.53 per share, for the three months ended June 30, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-014951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.